Table 1

Subgroup analyses of TGF-α and PGE2 data according to TGF-α response

TGF-α stainingPGE2 (pg/mg/min)
BaselineaAfter ASAaAfter placeboaBaselineAfter ASAAfter placebo
TGF-α respondersb0.43 ± 0.090.20c ± 0.030.25 ± 0.0330 ± 1812d ± 6.642 ± 22
TGF-α nonresponders0.30 ± 0.040.33 ± 0.050.33 ± 0.057.2 ± 2.12.6 ± 1.528 ± 21
  • a Data represent values are a 1-month placebo run-in period (baseline), after 3 months of consuming 81 mg of aspirin per day (after ASA), and after a 3-month placebo washout period (after placebo).

  • b Responders (n = 6), individuals with >25% change in TGF-α immunoreactivity after aspirin treatment; nonresponders (n = 4), individuals with <25% change.

  • c P < 0.05 versus baseline values.

  • d P < 0.05 versus baseline values and after placebo values.